

*miR-26a* Limits Muscle Wasting and Cardiac Fibrosis  
via microRNA Transfer in Chronic Kidney Disease

Theranostics

9, 1864-1877

DOI: 10.7150/thno.29579

Citation Report

#	ARTICLE	IF	CITATIONS
1	Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis. <i>Theranostics</i> , 2019, 9, 4740-4755.	4.6	112
2	Exogenous miR-26a suppresses muscle wasting and renal fibrosis in obstructive kidney disease. <i>FASEB Journal</i> , 2019, 33, 13590-13601.	0.2	48
3	Skeletal muscle wasting in chronic kidney disease: the emerging role of microRNAs. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1469-1478.	0.4	21
4	Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. <i>Theranostics</i> , 2020, 10, 411-425.	4.6	97
5	Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p/MFN1 axis. <i>Theranostics</i> , 2020, 10, 1415-1432.	4.6	65
6	Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF- $\kappa$ B/NLRP3 Pathway. <i>Frontiers in Pharmacology</i> , 2020, 11, 1080.	1.6	28
7	Exosome: a significant nano-scale drug delivery carrier. <i>Journal of Materials Chemistry B</i> , 2020, 8, 7591-7608.	2.9	108
8	Exogenous bone marrow derived-putative endothelial progenitor cells attenuate ischemia reperfusion-induced vascular injury and renal fibrosis in mice dependent on pericytes. <i>Theranostics</i> , 2020, 10, 12144-12157.	4.6	11
9	MicroRNA-26a Protects the Heart Against Hypertension-Induced Myocardial Fibrosis. <i>Journal of the American Heart Association</i> , 2020, 9, e017970.	1.6	17
10	Exosomes in Nephropathies: A Rich Source of Novel Biomarkers. <i>Disease Markers</i> , 2020, 2020, 1-12.	0.6	11
11	Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 577010.	1.8	16
12	Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors. <i>Nanomedicine</i> , 2020, 15, 2149-2170.	1.7	19
13	Dose-effect relationship and molecular mechanism by which BMSC-derived exosomes promote peripheral nerve regeneration after crush injury. <i>Stem Cell Research and Therapy</i> , 2020, 11, 360.	2.4	41
14	The Protective Role of Klotho in CKD-Associated Cardiovascular Disease. <i>Kidney Diseases (Basel)</i> , 2020, 11, 107-114.	1.2	24
15	Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease. <i>FASEB Journal</i> , 2020, 34, 8296-8309.	0.2	8
16	DR-region of Na <sup>+</sup> /K <sup>+</sup> -ATPase is a target to ameliorate hepatic insulin resistance in obese diabetic mice. <i>Theranostics</i> , 2020, 10, 6149-6166.	4.6	8
17	Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. <i>Theranostics</i> , 2020, 10, 3905-3924.	4.6	33
18	Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy. <i>Journal of Biological Chemistry</i> , 2020, 295, 12868-12884.	1.6	61

#	ARTICLE	IF	CITATIONS
20	Macrophage-Derived Exosomal Mir-155 Regulating Cardiomyocyte Pyroptosis and Hypertrophy in Uremic Cardiomyopathy. <i>JACC Basic To Translational Science</i> , 2020, 5, 148-166.	1.9	49
21	Going micro in CKD-related cachexia. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1462-1464.	0.4	1
22	Exogenous miR-29a Attenuates Muscle Atrophy and Kidney Fibrosis in Unilateral Ureteral Obstruction Mice. <i>Human Gene Therapy</i> , 2020, 31, 367-375.	1.4	24
23	Do exosomes play role in cardiovascular disease development in hematological malignancy?. <i>Molecular Biology Reports</i> , 2020, 47, 5487-5493.	1.0	8
24	The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1405-1414.	0.7	2
25	Engineering approaches for effective therapeutic applications based on extracellular vesicles. <i>Journal of Controlled Release</i> , 2021, 330, 15-30.	4.8	45
26	The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. <i>Cells</i> , 2021, 10, 240.	1.8	56
27	What can urinary exosomes tell us?. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3265-3283.	2.4	26
28	In Vivo Stimulation of $\alpha_1$ - and $\alpha_2$ -Adrenoceptors in Mice Differentially Alters Small RNA Content of Circulating Extracellular Vesicles. <i>Cells</i> , 2021, 10, 1211.	1.8	4
29	Urinary Extracellular Vesicles for Renal Tubular Transporters Expression in Patients With Gitelman Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 679171.	1.2	7
30	Mechanism of bone marrow mesenchymal stem cells secreting miR-26a exosomes affecting high glucose-induced skin fibroblasts function by regulating TLR4/NF- $\kappa$ B signaling. <i>Inflammation Research</i> , 2021, 70, 811-821.	1.6	5
31	Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics. <i>Cells</i> , 2021, 10, 1596.	1.8	33
32	miR-320a in serum exosomes promotes myocardial fibroblast proliferation via regulating the PI3K/Akt/mTOR signaling pathway in HEH2 cells. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 873.	0.8	11
33	Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 923-938.	2.3	44
34	Downregulation of let-7 by Electrical Acupuncture Increases Protein Synthesis in Mice. <i>Frontiers in Physiology</i> , 2021, 12, 697139.	1.3	5
35	Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715258.	1.1	39
36	DNMT1-Induced miR-152-3p Suppression Facilitates Cardiac Fibroblast Activation in Cardiac Fibrosis. <i>Cardiovascular Toxicology</i> , 2021, 21, 984-999.	1.1	10
37	Roles of Skeletal Muscle-Derived Exosomes in Organ Metabolic and Immunological Communication. <i>Frontiers in Endocrinology</i> , 2021, 12, 697204.	1.5	18

#	ARTICLE	IF	CITATIONS
38	Role of miRNA and lncRNAs in organ fibrosis and aging. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112132.	2.5	72
39	Dysregulations of miR-503-5p and Wnt/ $\beta$ -catenin pathway coordinate in mediating cadmium-induced kidney fibrosis. <i>Ecotoxicology and Environmental Safety</i> , 2021, 224, 112667.	2.9	8
40	The Multifunctionality of Exosomes; from the Garbage Bin of the Cell to a Next Generation Gene and Cellular Therapy. <i>Genes</i> , 2021, 12, 173.	1.0	12
41	Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer. <i>Pharmacological Research</i> , 2020, 157, 104843.	3.1	37
42	MicroRNAs as potential therapeutic targets for muscle wasting during cancer cachexia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2020, 23, 157-163.	1.3	7
43	Role of Exosomal miRNAs in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 592412.	1.1	26
44	Exosomes, a New Star for Targeted Delivery. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751079.	1.8	104
45	Non-coding RNA basis of muscle atrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1066-1078.	2.3	22
46	Roles of Exosomes in Cardiac Fibroblast Activation and Fibrosis. <i>Cells</i> , 2021, 10, 2933.	1.8	9
47	Pathophysiological mechanisms leading to muscle loss in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 138-152.	4.1	56
48	A systematic review and meta-analysis of murine models of uremic cardiomyopathy. <i>Kidney International</i> , 2022, 101, 256-273.	2.6	13
49	Exosomes and Exosomal Non-coding RNAs Are Novel Promises for the Mechanism-Based Diagnosis and Treatments of Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 782451.	1.1	6
50	MicroRNA-451a attenuates angiotensin II-induced cardiac fibrosis and inflammation by directly targeting T-box1. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 257-269.	1.3	8
51	TLR13 contributes to skeletal muscle atrophy by increasing insulin resistance in chronic kidney disease. <i>Cell Proliferation</i> , 2022, 55, e13181.	2.4	5
52	Characterization of the microRNA Expression Profiles in the Goat Kid Liver. <i>Frontiers in Genetics</i> , 2021, 12, 794157.	1.1	2
53	Biogenesis and function of extracellular vesicles in pathophysiological processes of skeletal muscle atrophy. <i>Biochemical Pharmacology</i> , 2022, 198, 114954.	2.0	38
55	Functional Extracellular Vesicles for Regenerative Medicine. <i>Small</i> , 2022, 18, e2106569.	5.2	22
56	Regenerative medicine 2.0: extracellular vesicle-based therapeutics for musculoskeletal tissue regeneration. <i>Journal of the American Veterinary Medical Association</i> , 2022, 260, 683-689.	0.2	3

#	ARTICLE	IF	CITATIONS
57	Extracellular vesicle-mediated bidirectional communication between heart and other organs. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H769-H784.	1.5	19
58	MicroRNAs in cardiovascular diseases. Medical Review, 2022, 2, 140-168.	0.3	1
59	Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implicationsâ€”A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 6047.	1.8	16
60	MiR-155 deficiency protects renal tubular epithelial cells from telomeric and genomic DNA damage in cisplatin-induced acute kidney injury. Theranostics, 2022, 12, 4753-4766.	4.6	12
61	<scp>MicroRNA</scp>â€”38â€”p as a therapeutic target in cardiac fibrosis through <scp>FGFR2</scp> suppression. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	11
62	Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
63	Extracellular vesicles for renal therapeutics: State of the art and future perspective. Journal of Controlled Release, 2022, 349, 32-50.	4.8	20
64	Non-coding RNAs: Important participants in cardiac fibrosis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
65	Shared and Divergent Epigenetic Mechanisms in Cachexia and Sarcopenia. Cells, 2022, 11, 2293.	1.8	8
66	Long-term culture of patient-derived cardiac organoids recapitulated Duchenne muscular dystrophy cardiomyopathy and disease progression. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	13
67	MicroRNA-based therapeutic strategies for chronic kidney disease and uremic cardiomyopathy. , 2022, , 563-600.		0
68	Biomaterials to promote vascularization in tissue engineering organs and ischemic fibrotic diseases. , 2022, 1, .		2
69	What do we actually know about exosomal microRNAs in kidney diseases?. Frontiers in Physiology, 0, 13, .	1.3	1
70	Role of exosomes and exosomal microRNA in muscleâ€”Kidney crosstalk in chronic kidney disease. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
71	Ultrasound-assessed diaphragm dysfunction predicts clinical outcomes in hemodialysis patients. Scientific Reports, 2022, 12, .	1.6	2
72	Exosomes as Potential Functional Nanomaterials for Tissue Engineering. Advanced Healthcare Materials, 2023, 12, .	3.9	10
73	Exosomeâ€”encapsulated miRâ€”26a attenuates aldosteroneâ€”induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. International Journal of Molecular Medicine, 2022, 51, .	1.8	8
74	<i>Bacteroides plebeius</i> improves muscle wasting in chronic kidney disease by modulating the gutâ€”renal muscle axis. Journal of Cellular and Molecular Medicine, 2022, 26, 6066-6078.	1.6	6

#	ARTICLE	IF	CITATIONS
75	Bibliometric analysis of scientific papers on extracellular vesicles in kidney disease published between 1999 and 2022. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
76	Exosome-mediated regulatory mechanisms in skeletal muscle: a narrative review. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 1-14.	1.3	5
77	Chronic kidney disease-induced muscle atrophy: Molecular mechanisms and promising therapies. <i>Biochemical Pharmacology</i> , 2023, 208, 115407.	2.0	12
78	Can Extracellular Vesicles as Drug Delivery Systems Be a Game Changer in Cardiac Disease?. <i>Pharmaceutical Research</i> , 2023, 40, 889-908.	1.7	11
79	The Role of NLRP3 Inflammasome in IgA Nephropathy. <i>Medicina (Lithuania)</i> , 2023, 59, 82.	0.8	2
80	Potential Therapeutic Strategies for Skeletal Muscle Atrophy. <i>Antioxidants</i> , 2023, 12, 44.	2.2	12
81	MicroRNA-26a-5p Restoration Ameliorates Unilateral Ureteral Obstruction-Induced Renal Fibrosis in Mice Through Modulating TGF- $\beta$ 2 Signaling. <i>Laboratory Investigation</i> , 2023, 103, 100131.	1.7	3
82	Human Keratinocyte-Derived Exosomal MALAT1 Promotes Diabetic Wound Healing by Upregulating MFGE8 via microRNA-1914-3p. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 949-970.	3.3	4
83	miRNAs in Uremic Cardiomyopathy: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5425.	1.8	5
84	Circulating non-coding RNAs in chronic kidney disease and its complications. <i>Nature Reviews Nephrology</i> , 2023, 19, 573-586.	4.1	5
93	Extracellular Vesicles for Muscle Atrophy Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 119-126.	0.8	0
96	Extracellular Vesicles in Kidney Disease. <i>Physiology</i> , 0, , .	4.0	0